Gefitinib warning

July 2005
CMAJ: Canadian Medical Association Journal;7/19/2005, Vol. 173 Issue 2, p141
Academic Journal
Reports that access in the U.S. to the AstraZeneca lung cancer drug gefitinib has been limited to users and those who previously found it effective. Results of a trial comparing gefitinib with placebo in patients with non-small-cell lung cancer; Reason behind the decision of Health Canada to keep gefinitib on the market.


Related Articles

  • Clinical Trial of Iressa.  // FDA Consumer;Mar/Apr2005, Vol. 39 Issue 2, p4 

    Focuses on the findings of a clinical trial conducted by AstraZeneca Pharmaceuticals comparing the drug Iressa with a placebo. Involvement of people with non-small cell lung cancer in the study; Therapeutic applications of Iressa; Requirements of the U.S. Food and Drug Administration to approve...

  • Gefitinib not noninferior to docetaxel for NSCLC.  // Reactions Weekly;10/20/2007, Issue 1174, p2 

    This article reports on the move of AstraZeneca to issue a "Dear Healthcare Professional" letter about the failure of gefitinib, a drug whose brand name is Iressa, to demonstrate noninferiority versus docetaxel in improving overall survival in patients with non-small cell lung cancer. It...

  • Minority Report. Davies, Kevin // Bio-IT World;Jun2004, Vol. 3 Issue 6, p6 

    Focuses on the effects of the Iressa drug developed by the Astrazeneca company on lung cancer patients. Failure of the Iressa drug to affect the majority of lung cancer patients; Findings from a clinical trial that patients who respond to Iressa have acquired mutations in the gene for the...

  • Bevacizumab Plus Platinum-Based Chemotherapy: In Advanced Non-Small Cell Lung Cancer. Wagstaff, Antona I.; Keam, Susan J.; McCormack, Paul L. // BioDrugs;2009, Vol. 23 Issue 3, p187 

    Bevacizumab is a recombinant, humanized vascular endothelial growth factor (VEGF) monoclonal antibody that inhibits tumor growth and tumor metastases. VEGF stimulates angiogenesis in tumors, is involved in early metastatic processes, and is overexpressedin non-small cell lung cancer (NSCLC). The...

  • Molecule of the Month. Lindsley, Craig W.; Thomas, Ashley L. // Current Topics in Medicinal Chemistry;Jan2008, Vol. 8 Issue 1, p62 

    Overcoming Resistance. Over four years ago, on May 2, 2003, the FDA approved Iressa� (gefitinib) by AstraZeneca for the treatment of non-small cell lung cancer (NSCLC) in patients that failed to respond to two other types of chemotherapy. The potential therapeutic benefit of Iressa�, a...

  • AstraZeneca: Iressa inspires.  // PharmaWatch: Cancer;June 2003, Vol. 2 Issue 6, p19 

    No abstract available.

  • AstraZeneca: withdrawal of Iressa application adds to woes.  // PharmaWatch: Cancer;Feb2005, Vol. 4 Issue 2, p8 

    The article reports on the uncertainty faced by AstraZeneca PLC after withdrawing from the European Marketing Authorisation Application for Iressa, a lung cancer treatment, because it failed in the clinical trial analysis. AstraZeneca believed that its Iressa Survival Evaluation in Lung cancer...

  • AstraZeneca: blockbuster status remains distant for Iressa.  // PharmaWatch: Cancer;February 2004, Vol. 3 Issue 2, p7 

    Reports on the approval of AstraZeneca's Iressa for the treatment of advanced non-small cell lung cancer in Canada. Mechanism of action of the drug.

  • Health Canada looks to approve AstraZeneca lung cancer drug.  // PharmaWatch: Cancer;February 2004, Vol. 3 Issue 2, p9 

    Reports on Health Canada's approval of AstraZeneca's Iressa drug used in the treatment of non-small cell lung cancer. Mechanism of action.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics